Pharmacogenetics of etanercept in rheumatoid arthritis

Pharmacogenomics

Volumn 9, Issue 8, 2008, Pages 1011-1015

  Danila, Maria I ^a   Hughes, Laura B ^a   Bridges Jr , S Louis ^a  

^a The University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ATLIZUMAB; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EPITOPE; ETANERCEPT; FC RECEPTOR; GOLIMUMAB; HLA DR ANTIGEN; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; LYMPHOTOXIN; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 1A; TUMOR NECROSIS FACTOR RECEPTOR 1B;

ANKYLOSING SPONDYLITIS; CLINICAL TRIAL; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; INDIVIDUALIZATION; JUVENILE RHEUMATOID ARTHRITIS; MONOTHERAPY; PHARMACOGENETICS; POPULATION GENETICS; PROMOTER REGION; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT PLANNING;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOGLOBULIN G; PHARMACOGENETICS; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 50149094664     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.8.1011     Document Type: Review

References (22)

1. Kay J, Matteson EL, Dasgupta B et al.: Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 58(4), 964-975 (2008).
2. Kaushik VV, Moots RJ: CDP-870 (certolizumab) in rheumatoid arthritis. Expert Opin. Biol. Ther. 5(4), 601-606 (2005).
3. Smolen JS, Beaulieu A, Rubbert-Roth A et al.: Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371(9617), 987-997 (2008).
4. Bridges SL Jr: Personalized medicine in rheumatoid arthritis: hopes and challenges. Bull. NYU Hosp. Jt Dis. 65(3), 174-177 (2007).
5. Saag KG, Teng GG, Patkar NM et al.: American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 59(6), 762-784 (2008).
6. Padyukov L, Lampa J, Heimburger M et al.: Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann. Rheum. Dis. 62(6), 526-529 (2003).
7. Schotte H, Schluter B, Drynda S et al.: Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis. Ann. Rheum. Dis. 64(4), 575-581 (2005).
8. Bathon JM, Martin RW, Fleischmann RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343, 1586-1593 (2000).
9. Criswell LA, Lum RF, Turner KN et al.: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 50(9), 2750-2756 (2004).
10. Gregersen PK, Silver J, Winchester R: The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 30, 1205-1213 (1987).
11. Kang CP, Lee KW, Yon DH, Kang C, Bae SC: The influence of a polymorphism at position -857 of the tumour necrosis factor-α gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford) 44(4), 547-552 (2005).
12. de Vries N, Tak PP: The response to anti-TNF-α treatment: gene regulation at the bedside. Rheumatology (Oxford) 44(6), 705-707 (2005).
13. Seitz M, Wirthmuller U, Moller B, Villiger PM: The -308 tumour necrosis factor-α gene polymorphism predicts therapeutic response to TNFα-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 46(1), 93-96 (2007).
14. Guis S, Balandraud N, Bouvenot J et al.: Influence of -308 A/G polymorphism in the tumor necrosis factor a gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum. 57(8), 1426-1430 (2007).
15. Schmeling H, Horneff G: Tumour necrosis factor-α promoter polymorphisms and etanercept therapy in juvenile idiopathic arthritis. Rheumatol. Int. 27(4), 383-386 (2007).
16. Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D: Fcγ receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor α-blocking agents. Arthritis Rheum. 52(9), 2693-2966 (2005).
17. Kastbom A, Bratt J, Ernestam S et al.: Fcγ receptor type IIIA genotype and response to tumor necrosis factor α-blocking agents in patients with rheumatoid arthritis. Arthritis Rheum. 56(2), 448-452 (2007).
18. Bridges SL Jr: Genetic markers of treatment response in rheumatoid arthritis. Arthritis Rheum. 50, 1019-1022 (2004).
19. Hughes LB, Morrison D, Kelley JM et al.: The HLA-DRB1 shared epitope is associated with susceptibility to rheumatoid arthritis in African-Americans through European genetic admixture. Arthritis Rheum. 58(2), 349-358 (2008).
20. Roden DM, Altman RB, Benowitz NL et al.: Pharmacogenomics: challenges and opportunities. Ann. Intern. Med. 145(10), 749-757 (2006).
21. Plenge RM, Seielstad M, Padyukov L et al.: TRAF1-C5 as a risk locus for rheumatoid arthritis - a genomewide study. N. Engl. J. Med. 357(12), 1199-1209 (2007).
22. Thomson W, Barton A, Ke X et al.: Rheumatoid arthritis association at 6q23. Nat. Genet. 39(12), 1431-1433 (2007).